- “Screening is the first line of defense,” said IZO CEO Robert Thast, who noted that company’s Breast CT technology can detect cancers as small as two millimeters.
- Thast summarized Izotropic’s recent advances in artificial intelligence.
- Company’s commercialization plans start in Europe and then expand to U.S, with focus on selling primarily to hospitals, medical facilities and imaging clinics.
A new episode of the BioMedWire Podcast shines a spotlight on Izotropic (CSE: IZO) (OTCQB: IZOZF) and its innovative approach to breast cancer imaging. Featuring IZO CEO Robert Thast, the podcast (ibn.fm/JUWtD) reveals how Izotropic’s proprietary Breast CT technology could transform early detection, improve patient outcomes and set the company on a trajectory toward commercial success in major healthcare markets. With both its groundbreaking science and its business vision on display, the conversation captures why Izotropic is gaining attention across the medical imaging sector.
During the interview, Thast underscored the urgency of improving detection rates for breast cancer, one of the most common cancers among women worldwide. “Screening is the first line of defense,” he noted. “It’s where lives are saved or not. . . Current standard of care misses a lot of cancers and is not particularly good at finding aggressive cancers in the early stages. With our Breast CT technology, we can see cancers as small as two millimeters. Current standard of care is 11 millimeters average. That’s a big difference—between 12 and 18 months earlier—which could mean the difference between finding it and treating it or having it get past the point of no return.”
Thast also summarized Izotropic’s recent advances in artificial intelligence, observing that the company has made breakthroughs which differentiate it from other imaging companies and strengthen its long-term positioning. “We have recently announced an AI development and capability that no one else has and may never have,” he said. “We expect this technology will become increasingly accepted over time, and the majors will have to get involved if they intend to maintain their market share.
“In terms of protecting our position, we have a portfolio of patents, trade secrets and products,” he continued. “The majors are certainly going to have the muscle to get in the game, there’s no question about that. I think it would be a lot less expensive for them to buy something like IzoView, and I expect that’s what will happen as we move forward. We believe we will be a takeover target.”
Thast also outlined Izotropic’s commercialization strategy, which starts in Europe before expanding to the United States. “From a revenue standpoint, our launch will be focused primarily on selling to hospitals, medical facilities and imaging clinics,” he explained. “Those will be focused on the EU first, followed by the United States. . . . Between the U.S. and Europe, you’re looking at almost 50% of the world market for one of these devices. . . . The FDA study is a clear mandate. If we secure FDA approval, really the world is wide open to us.”
The podcast conversation reinforced Izotropic’s dual mission: improving outcomes for patients while building value for stakeholders. With breast cancer remaining a leading cause of cancer death worldwide, better imaging technologies are critical to saving lives.
Izotropic is a medical imaging company focused on the development and commercialization of advanced breast CT technology. Its flagship device, IzoView, is designed to produce true 3D images of the breast with high resolution and accuracy, without the compression required in mammography. The goal is to address long-standing limitations in current breast cancer screening methods and give clinicians a powerful tool for finding cancers earlier, particularly aggressive tumors that are often missed until they are more advanced.
Izotropic’s IzoView system could become a significant advancement in this space by detecting tumors earlier, reducing false negatives, and supporting oncologists with clearer, faster, and more accurate imaging. At the same time, its IP portfolio, AI capabilities, and early commercial plans create pathways for growth and potential strategic partnerships.
For Izotropic, the stakes are high, but the opportunity is enormous. By offering a solution that may close the gap between early detection and improved survival, the company is positioning itself at the center of science, healthcare and market demand.
For more information, visit the company’s website at www.IzoCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF
